Phase 3 · NCT05931367
TRIUMPH-4
A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
Registry record
Trial details
- Trial
- TRIUMPH-4
- ClinicalTrials.gov ID
- NCT05931367
- Indication
- Obesity, Overweight, Osteo Arthritis Knee
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 445
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 49 sites · Australia, Canada, Mexico, Spain, United Kingdom, United States
- Study start
- 1 Aug 2023
- Primary completion
- 14 Nov 2025
- Study completion
- 14 Nov 2025
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 21 Jan 2026
Endpoints
Primary
Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score; Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in the WOMAC Physical Function Subscale Score; Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Body Mass Index (BMI); Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Short Form 36-Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score; Change from Baseline in Average Pain Intensity Numeric Rating Score (API-NRS) Score; Change from Baseline in Worst Pain Intensity Numeric Rating Score (WPI-NRS) Score